|
Absci Corp (NASDAQ: ABSI) |
|
Absci Corp
ABSI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Absci growth rates, revenue grew
by 128.63 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 3042
Medical Laboratories industry recorded
growth of revenues by 6.58 %
Absci net loss increased from $-22 millions, to $-27 millions in III. Quarter 2024,
• More on ABSI's Growth
|
|
Absci realized a net loss in trailing twelve months.
Absci realized cash reduction of $ -0.28 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 126.12.
Medical Laboratories industry's Price to Sales ratio is at 2.55.
• More on ABSI's Valuation
|
|
|
|
|
Absci realized net loss in trailing twelve months.
Absci realized cash outflow of $ -0.28per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 126.12.
Medical Laboratories industry's Price to Sales ratio is at 2.55.
Absci Price to Book Ratio is at 2.64 lower than Industry Avg. of 29.17. and higher than S&P 500 Avg. of 0.01
• More on ABSI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com